Navigation Links
ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
Date:3/10/2008

SALT LAKE CITY, March 10 /PRNewswire/ -- ZARS Pharma, Inc. announced today the completion of an agreement providing Galderma Pharma S.A. the exclusive promotion and distribution rights for all markets outside the United States and Canada for Pliaglis(TM) (lidocaine and tetracaine) Cream 7%/7%, a topical anesthetic that provides effective and safe local anesthesia in patients undergoing potentially painful cosmetic and other skin treatment procedures. This agreement complements the previously announced agreement between ZARS Pharma and Galderma for the promotion and distribution rights of Pliaglis in the United States and Canada and effectively grants Galderma exclusive worldwide rights for Pliaglis.

Pliaglis has been approved by the FDA for the local anesthesia of intact skin before various superficial dermatological procedures such as dermal filler procedures, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal and is anticipated to be the subject of marketing applications to be filed with additional regulatory authorities in key markets later in 2008. Other therapies for topical anesthesia are often characterized as having slow onset of action, sporadic and shallow anesthesia (especially in highly vascularized regions such as the face), short duration of effect and inadequate safety profiles. Pliaglis is indicated for use in adults and is applied for 20 to 30 minutes prior to procedures such as dermal filler injections or facial laser resurfacing, and for 60 minutes for procedures such as laser-assisted tattoo removal.

"We are delighted to announce the worldwide license agreement for Pliaglis with Galderma, a worldwide leader in the field of dermatology," said Robert Lippert, President and Chief Executive Officer of ZARS Pharma. "We believe that Pliaglis will become the topical anesthetic of choice for these procedures and will become an integral and important tool for physicians worldwide."

About Pliag
'/>"/>

SOURCE ZARS Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... September 18, 2014 First Choice ... emergency rooms in the United States, named Douglas J. ... Missouri City-Lakes facility. , “We are pleased to ... medical director of our new Missouri City-Lakes facility,” said ... Choice Emergency Room. , Dr. Harrison received his ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 The Nautilus/ASG ... from active, to medium, and even long term data ... for any length of time. This includes media and ... data. When used together, Nautilus and ASG-Digital Archive will ... content. , "storageFOUNDRY is pleased to work with ...
(Date:9/17/2014)... 2014 The global ablation technologies market ... from 2014 to 2019. Although mature markets (such as ... shares in the ablation technologies market in 2014, the ... CAGR of 12.8% in the next five years.Factors such ... growing number of hospitals and surgical centers, and the ...
(Date:9/17/2014)... 18, 2014 Dr. Shalev is a Texas ... Houston to study at the University of Texas, and graduated ... she realized her real passion lay in dentistry, and she ... the University of Texas Health Science Center at Houston School ... is a member of The Greater Houston Dental Society, and ...
(Date:9/17/2014)... New York, NY (PRWEB) September 18, 2014 ... than 5.9 million tons of medical waste in 2014. ... directly disposed of in landfills along with municipal solid ... the disposal of regulated medical waste (RMW). This includes ... fluids or other potentially infectious materials. As a result ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Douglas J. Harrison as Medical Director of Missouri City - Lakes, Texas Facility 2Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 2Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:Medical Waste Disposal Services in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Medical Waste Disposal Services in the US Industry Market Research Report Now Available from IBISWorld 3
... Society report outlines 21 challenges and needs for global tobacco ... and expertise needed to reduce the rising tide of tobacco ... are the target of the multinational tobacco industry. The report ... issue of CA: A Cancer Journal for Clinicians . ...
... Genital herpes caused by a reactivation of herpes simplex ... lesion in one specific area of the genital region. ... frequently reactivate throughout the genital tract, an important new ... prevention. Now available online ( http://www.journals.uchicago.edu/doi/abs/10.1086/650302 ), the study ...
... is associated with increased cancer risk. The most ... noted for a common form of liver cancer called ... obesity in mice, researchers at the University of California, ... obesity is tumor-promoting and have obtained evidence that this ...
... Hasbro Children,s Research Center and Hasbro Children,s Hospital researchers ... from The Eunice Kennedy Shriver National Institute of Child ... of asthma on the sleep quality and academic performance ... pediatric researchers, led by Daphne Koinis-Mitchell, PhD, to evaluate ...
... reduce the transmission of influenza-like illness during flu season. ... online ( http://www.journals.uchicago.edu/doi/abs/10.1086/650396 ), published in the Feb. 15 ... In an influenza pandemic, vaccination may not be ... is why scientists need to understand how effective other ...
... The BC Centre for Disease Control has launched ... the pandemic H1N1 flu virus has evolved in British ... months. This project capitalizes on BC,s expertise and ... genomes from circulating influenza viruses collected in British Columbia ...
Cached Medicine News:Health News:Global tobacco report outlines 21 challenges for 21st century 2Health News:Global tobacco report outlines 21 challenges for 21st century 3Health News:Study shows genital herpes virus reactivates widely throughout genital tract 2Health News:Link between obesity and enhanced cancer risk elucidated 2Health News:New research will examine link between childhood asthma, sleep and school performance 2Health News:Study finds face masks and hand hygiene can help limit influenza's spread 2Health News:Genomic surveillance of pandemic H1N1 2
(Date:9/17/2014)... , Sept. 17, 2014  Decision ... colitis (CD/UC) patients eligible for biologic therapy, ... a biologic. Surveyed gastroenterologists cite patients, discomfort ... for low penetration rates, followed by cost-related ... UC patients receiving biologics, Janssen Biotech,s Remicade ...
(Date:9/17/2014)... Sept. 17, 2014  Rebiotix Inc. announced this morning that ... product candidate, RBX2660 (microbiota suspension) will be presented in two ... in Philadelphia from October 8-12. ... the poster session on Thursday, October 9, 2014: ... Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety ...
(Date:9/17/2014)... , Sept. 17, 2014   OTEMR, Inc. , ... Complete EHR certification, which designates that the software is ... 1 and Stage 2 Meaningful Use measures required to ... Act (ARRA).  ONETOUCH EMR 2.0 was certified on July ... of the National Coordinator-Authorized Certification Body (ONC-ACB) and is ...
Breaking Medicine Technology:The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3
... recommendations for knee and ... hip osteoarthritis, ... MT. LAUREL, N.J., Feb. 19 A newly released set ... worldwide who live in pain due to inconsistent treatment,approaches and confusion ...
... Feb. 19 Joseph F. Finn, Jr.,CPA, the ... announced,today the design of a clinical trial to ... approved antibiotics. Rifalazil, the,most potent anti-chlamydial agent that ... treatment option for Chlamydia STD. The insidious aspect,of ...
Cached Medicine Technology:Osteoarthritis: Which Treatments Work and Which Don't? 2Osteoarthritis: Which Treatments Work and Which Don't? 3ActivBiotics Outlines a Clinical Path Forward to Examine if Rifalazil Is Superior to Azithromycin in the Treatment of Chlamydia STD 2
... Ultracentrifuge power for small-volume samples. With ... method of removing chylomicrons (fat particles in ... results for lipemic clarification. Lipemic samples can ... need for sendouts. The easy-to-operate tabletop ...
... Dimension Xpand integrated chemistry system brings ... to the smaller laboratory. A model ... Xpand integrated chemistry system features state-of-the-art ... low-volume testing environment, in a flexible, ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
... Dimension clinical chemistry integrated systems combine the ... cartridge, the power of the Multiply and ... the heterogeneous module to meet the challenges ... broad test menus, the systems can meet ...
Medicine Products: